Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of ...

Welcome to the CytomX Therapeutics fourth-quarter 2024 and financial results call. Please be advised that today's call is being recorded. I would now like to hand the call over to your host for today, ...

Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignifica ...

DelveInsight’s, “Mesothelioma Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on ...

(NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., (“Adimune”) ...

SHANGHAI, China I March 6, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...

More than 160 motorcyclists were stopped for checks during the joint operation. Read more at straitstimes.com.

Moore, MD, discusses the exciting advancements in endometrial cancer treatment, particularly over the past 2 years, as she prepares for the 2025 Society of Gynecologic Oncology Annual Meeting on Women ...

USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never ...